Subscribe

Fabrizio Galimberti, MD, PhD: The Importance of Targeted Therapy for GPP Treatment

Generalized Pustular Psoriasis
Fabrizio Galimberti, MD, PhD, reviews the molecular biology behind spesolimab for the treatment of generalized pustular psoriasis (GPP). He highlights the distinction between psoriasis and GPP, while discussing the role that the interleukin-36 pathway plays in inflammation. Dr. Galimberti emphasizes the importance of targeted treatment for flare reduction and improved outcomes in GPP management.

More JCAD Podcasts:

Tina Bhutani, MD, MAS, FAAD: Use of Spesolimab for Generalized Pustular Psoriasis

Bruce Strober, MD, PhD, FAAD: Providing Care With Risankizumab in Psoriasis

James Del Rosso, DO, Diego Ruiz Dasilva, MD, and Graham Litchman, DO, MS: Management of Severe Nail Psoriasis and Early Psoriatic Arthritis

James Del Rosso, DO, and David Cotter, MD, PhD: Clinical Management of Conjunctivitis, Erythema, and Arthralgia in AD

Ted Lain, MD, MBA: Long-Term Results of Deuruxolitinib for Alopecia Areata

Amy McMichael, MD: Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata

Graham Litchman, DO, MS: Understanding Long-Term Treatment Success in a Patient With Psoriasis

Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment